Ignite Creation Date:
2024-05-06 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05926427
Status:
RECRUITING
Last Update Posted:
2023-09-05
First Post:
2023-06-22
Brief Title:
Orelabrutinib Combined With Rituximab and Chemotherapy for RelapsedRefractory B-Cell Lymphoma Patients With Central Nervous System Involvement
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Organization Data
Organization:
Ruijin Hospital
Class:
OTHER
Study ID:
Oreo
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ruijin Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Zhao Weili
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Ruijin Hospital
Old Name:
None
Old Organization:
None